Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Cytokinetics (CYTK)

Cytokinetics Q1 net loss widens to $161.4 million; FDA extends aficamten PDUFA

Mixed Impact 3 of 5 earnings Written later

Cytokinetics reported first quarter 2025 results, with revenue of $1.6 million, up from $0.8 million a year earlier, but a net loss of $161.4 million, or $(1.36) per share, versus a $135.6 million loss, or $(1.33) per share, in the first quarter of 2024. The FDA extended the review target date for aficamten in obstructive HCM to December 26, 2025, and the company maintained its full-year 2025 GAAP operating expense guidance of $670 million to $710 million.

Key points

  • Q1 2025 revenue was $1.6 million, compared with $0.8 million in Q1 2024.
  • Q1 2025 net loss was $161.4 million, or $(1.36) per share, compared with $135.6 million, or $(1.33) per share, a year earlier.
  • R&D expenses rose to $99.8 million from $81.6 million, and G&A expenses rose to $57.4 million from $45.5 million.
  • The FDA extended the aficamten PDUFA date to December 26, 2025; cash, cash equivalents and investments were about $1.1 billion at March 31, 2025.

The filing

CompanyCytokinetics (CYTK)
Form8-K, current report
Filed with the SECMay 6, 2025, 4:05 PM ET
Accession number0000950170-25-064432

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:57 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 06, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.